Last reviewed · How we verify

Calcipotriol plus betamethasone

LEO Pharma · Phase 3 active Small molecule

Calcipotriol plus betamethasone is a Vitamin D analogue plus corticosteroid combination Small molecule drug developed by LEO Pharma. It is currently in Phase 3 development for Plaque psoriasis, Psoriasis vulgaris.

Calcipotriol (a vitamin D analogue) and betamethasone (a corticosteroid) work together to reduce skin inflammation and normalize keratinocyte differentiation in psoriasis.

Calcipotriol (a vitamin D analogue) and betamethasone (a corticosteroid) work together to reduce skin inflammation and normalize keratinocyte differentiation in psoriasis. Used for Plaque psoriasis, Psoriasis vulgaris.

At a glance

Generic nameCalcipotriol plus betamethasone
SponsorLEO Pharma
Drug classVitamin D analogue plus corticosteroid combination
TargetVitamin D receptor (VDR) and glucocorticoid receptor (GR)
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 3

Mechanism of action

Calcipotriol activates vitamin D receptors to promote differentiation and reduce proliferation of skin cells, while betamethasone provides potent anti-inflammatory effects through glucocorticoid receptor activation. The combination addresses both the underlying pathophysiology and acute inflammation of psoriatic plaques, with synergistic efficacy superior to either agent alone.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Calcipotriol plus betamethasone

What is Calcipotriol plus betamethasone?

Calcipotriol plus betamethasone is a Vitamin D analogue plus corticosteroid combination drug developed by LEO Pharma, indicated for Plaque psoriasis, Psoriasis vulgaris.

How does Calcipotriol plus betamethasone work?

Calcipotriol (a vitamin D analogue) and betamethasone (a corticosteroid) work together to reduce skin inflammation and normalize keratinocyte differentiation in psoriasis.

What is Calcipotriol plus betamethasone used for?

Calcipotriol plus betamethasone is indicated for Plaque psoriasis, Psoriasis vulgaris.

Who makes Calcipotriol plus betamethasone?

Calcipotriol plus betamethasone is developed by LEO Pharma (see full LEO Pharma pipeline at /company/leo-pharma).

What drug class is Calcipotriol plus betamethasone in?

Calcipotriol plus betamethasone belongs to the Vitamin D analogue plus corticosteroid combination class. See all Vitamin D analogue plus corticosteroid combination drugs at /class/vitamin-d-analogue-plus-corticosteroid-combination.

What development phase is Calcipotriol plus betamethasone in?

Calcipotriol plus betamethasone is in Phase 3.

What are the side effects of Calcipotriol plus betamethasone?

Common side effects of Calcipotriol plus betamethasone include Skin irritation or burning at application site, Hypercalcemia (with excessive use), Local skin atrophy (from corticosteroid component), Folliculitis.

What does Calcipotriol plus betamethasone target?

Calcipotriol plus betamethasone targets Vitamin D receptor (VDR) and glucocorticoid receptor (GR) and is a Vitamin D analogue plus corticosteroid combination.

Related